Andrew R. Allen

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Elizabeth M. Swisher, Kevin Lin, Amit M. Oza et al. · The Lancet Oncology · 2016 · 1.2K citations · Full text

Medicine, Pharmacology, Pathology +6

Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer

Lecia V. Sequist, Jean‐Charles Soria, Jonathan W. Goldman et al. · New England Journal of Medicine · 2015 · 660 citations · Full text

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Annette O. Walter, Robert Tjin Tham Sjin, Henry J. Haringsma et al. · Cancer Discovery · 2013 · 622 citations · Full text

Heterogeneity Underlies the Emergence of <i>EGFR</i> T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

Zofia Piotrowska, Matthew J. Niederst, Chris Karlovich et al. · Cancer Discovery · 2015 · 453 citations · Full text

Assessment of <i>EGFR</i> Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

Chris Karlovich, Jonathan W. Goldman, Jong‐Mu Sun et al. · Clinical Cancer Research · 2016 · 178 citations · Full text